ASML Holding vs Bristol-Myers Squibb: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: ASML Holding and Bristol-Myers Squibb side by side

1. 1858Bristol-Myers Squibb

   Edward Robinson Squibb opens his Brooklyn laboratory

   Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.

2. 1887Bristol-Myers Squibb

   Bristol and Myers buy the Clinton Pharmaceutical Company

   Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.

3. 1898Bristol-Myers Squibb

   Bristol, Myers and Company is named

   The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.

4. 1944Bristol-Myers Squibb

   Penicillin at wartime scale

   Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.

5. 1984ASML Holding

   Founded as ASM Lithography in Eindhoven

   ASM Lithography starts operations on April 1, 1984 as a joint venture between Philips and ASM International, with the mandate to commercialize the PAS 2000 wafer stepper developed inside Philips.

6. 1986ASML Holding

   PAS 2500 stepper and the Carl Zeiss partnership

   ASML brings the PAS 2500 stepper to market with a new wafer alignment system developed by first chief scientist Steef Wittekoek, and establishes the optics partnership with Carl Zeiss that still supplies every ASML lithography system.

7. 1988ASML Holding

   ASM International withdraws and Philips funds a rescue

   With few customers and heavy cash consumption, ASM International decides to stop funding the joint venture while Philips launches a company-wide cost-cutting program.

8. 1989Bristol-Myers Squibb

   Bristol-Myers and Squibb merge

   Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.

9. 1991ASML Holding

   PAS 5500 platform turns the company around

   ASML launches the PAS 5500 platform, whose productivity and resolution win the first large orders from Intel and IBM under chief executive Willem Maris and take the company to profitability. PAS 5500 systems are still running in customer fabs decades later.

10. 1995ASML Holding

    IPO in Amsterdam and on Nasdaq

    ASML becomes a fully independent public company with a dual listing on the Amsterdam Stock Exchange and Nasdaq. Philips sells half of its shares at the IPO and divests the remainder over the following years.

11. 2001ASML Holding

    TWINSCAN platform launched and Silicon Valley Group acquired

    ASML introduces the TWINSCAN dual-stage architecture, which exposes one wafer while the next is measured and aligned, lifting throughput and overlay accuracy above competing systems.

12. 2003ASML Holding

    First immersion lithography system

    The TWINSCAN AT:1150i debuts as ASML's first immersion machine, projecting 193 nanometer light through a layer of ultrapure water between the lens and the wafer to raise resolution.

13. 2006Bristol-Myers Squibb

    CEO Peter Dolan removed over the Plavix deal

    After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.

14. 2009Bristol-Myers Squibb

    Medarex bought and Mead Johnson split off

    BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.

15. 2010ASML Holding

    First EUV prototype shipped

    ASML ships the TWINSCAN NXE:3100, its first extreme ultraviolet lithography tool, to the research facility of an Asian chipmaker.

16. 2011Bristol-Myers Squibb

    FDA approves Yervoy

    Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.

17. 2012ASML Holding

    Customer Co-Investment Program with Intel, TSMC and Samsung

    Intel, TSMC and Samsung acquire newly issued ASML shares equal to an aggregate 23 percent minority stake for ~$4.35 billion (3.85 billion euros) in cash, and separately commit ~$1.56 billion (1.38 billion euros) of R&D funding over five years dedicated to EUV…

18. 2012Bristol-Myers Squibb

    FDA approves Eliquis

    The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.

19. 2013ASML Holding

    Cymer acquisition completed and second-generation EUV shipped

    ASML completes the acquisition of Cymer, the San Diego supplier of the light sources used in its lithography systems, in a cash-and-stock deal valued at ~$2.2 billion (1.95 billion euros) when it was agreed in October 2012.

20. 2014Bristol-Myers Squibb

    FDA approves Opdivo

    The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.

21. 2017ASML Holding

    EUV enters high-volume manufacturing

    ASML begins shipping the production-ready TWINSCAN NXE:3400B after customers started ordering the NXE:3400 generation in batches in 2016, roughly two decades after EUV research began.

22. 2019ASML Holding

    Dutch government stops EUV exports to China

    The Netherlands does not renew ASML's export licence for EUV systems to China, the start of a widening export control regime.

23. 2019Bristol-Myers Squibb

    Celgene acquisition closes

    BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.

24. 2020Bristol-Myers Squibb

    MyoKardia deal and a GAAP loss

    BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.

25. 2022Bristol-Myers Squibb

    Turning Point bought as Revlimid generics arrive

    BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.

26. 2023ASML Holding

    First High-NA EUV system shipped

    ASML ships the first of its next-generation EUV systems with a numerical aperture of 0.55, the TWINSCAN EXE:5000, to Intel in Hillsboro, Oregon.

27. 2023Bristol-Myers Squibb

    Chris Boerner becomes CEO

    Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.

28. 2024ASML Holding

    Christophe Fouquet becomes chief executive

    Peter Wennink and Martin van den Brink step down as presidents of ASML on April 24, 2024 and Christophe Fouquet becomes president, chief executive officer and chair of the Board of Management.

29. 2024Bristol-Myers Squibb

    Karuna, Mirati and RayzeBio close; Cobenfy approved

    The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.

30. 2025ASML Holding

    Record year, first EXE:5200B and Mistral AI investment

    ASML reports total net sales of ~$37 billion (32.7 billion euros), up 15.6 percent, net income of ~$10.8 billion (9.6 billion euros), a gross margin of 52.8 percent and 535 systems sold, and closes the year with a backlog of ~$43.8 billion (38.8 billion euros)…

31. 2025Bristol-Myers Squibb

    BioNTech partnership, Orbital deal and $48.2B revenue

    BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.

32. 2026Bristol-Myers Squibb

    Guidance raised and merger reports denied

    On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.

Acquisitions

Questions about ASML Holding vs Bristol-Myers Squibb